Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 4/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320781 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTTBRD4 | |
| SCHEMBL16320771 | 0.90 | CYP3A4 (0.72) | CYP3A4CYP2B6SMN1; SMN2HTTBRD4 | |
| SCHEMBL16320772 | 0.90 | CYP3A4 (0.72) | CYP3A4CYP2B6SMN1; SMN2HTTBRD4 | |
| SCHEMBL16322092 | 0.86 | CYP3A4 (0.70) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16322089 | 0.86 | CYP3A4 (0.70) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL17841303 | 0.85 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL17841304 | 0.85 | CYP3A4 (0.69) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| SCHEMBL16356127 | 0.84 | CYP3A4 (0.67) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| Mavacamten SCHEMBL16322996 | 0.82 | CYP3A4 (1.00) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB | |
| Mavacamten SCHEMBL16356131 | 0.82 | CYP3A4 (1.00) | CYP3A4CYP2B6SMN1; SMN2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230338378-A1 | Methods of Administering Myosin Inhibitors | MyoKardia, Inc. | 2023-10-26 | — | — | US | disclosed |
| US-20230338378-A1 | Methods of Administering Myosin Inhibitors | MyoKardia, Inc. | 2023-10-26 | — | — | US | disclosed |
| CN-109384729-B | Pyrimidinedione compounds for cardiac disorders | 迈奥卡迪亚公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158027-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158027-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MYH10, MYH2, MYH14 | CYP3A4 4368/4885CYP2B6 4778/4885SMN1; SMN2 134/4885 |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
| US-20230338378-A1 | Methods of Administering Myosin Inhibitors | MYH2, MYLK2, MYH10 | CYP3A4 3078/4885CYP2B6 3439/4885SMN1; SMN2 283/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885SMN1; SMN2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.